NCT01884155

Allogeneic Umbilical Cord Blood Therapy for Stroke

Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Patients With Stroke

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: MinYoung Kim, M.D. · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with stroke.

Detailed description

Stroke is one of the most common etiologies causing disability in developed countries. There remains no proven treatments except tissue plasminogen activator currently. Based on promising results of cell therapy in animal stroke models, efforts to apply cell therapy for patients with stroke has been made. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for stroke.

Conditions

• Stroke

Interventions

Type	Name	Description
PROCEDURE	Allogeneic umbilical cord blood therapy

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-05-01
• Completion: 2015-12-01
• First posted: 2013-06-21
• Last updated: 2017-10-12

Locations

1 site across 1 country: South Korea